Neurosolutions in alliance with Argenta Discovery

Neurology focused research and development company, NeuroDiscovery Ltd, has formed an alliance with United Kingdom-based, Argenta Discovery Ltd.

Under the agreement, Argenta will gain preferential access to specialist electrophysiology and hERG testing services and expertise of Perth-based NeuroDiscovery's subsidiary, NeuroSolutions.

NeuroDiscovery said the collaboration would enable Argenta to provide its contract research clients with an expanded assay development and screening resource; either as part of an integrated drug discovery programme, or as a stand-alone service.

NeuroSolutions chief operating officer Dr Edward Stevens said Argenta Discovery had a well-earned reputation as a quality contract drug discovery service provider to the global pharmaceutical industry.

"NeuroSolutions is a recognised specialist in the electrophysiology and hERG screening fields, and our management team has over 30 years experience in the pharmaceutical and biotechnology sectors. This puts NeuroSolutions in a unique position to understand our clients' electrophysiological research needs, and fulfil their expectations. We are looking forward to assisting Argenta's contract research clients accelerate their drug discovery programmes."

Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells or tissues.

In parallel to running its service business, NeuroSolutions is also exploiting its in-house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain.

Founded in August 2000, Argenta Discovery has a contract research division which provides integrated drug discovery services, comprising medicinal chemistry, computer-aided drug design (CADD), biochemistry, in vitro screening and early ADME, to a range of leading pharmaceutical and biotechnology companies world-wide.

Argenta's proprietary therapeutics division has leading expertise in chronic respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD), Asthma and Cystic Fibrosis.